VAV Lipids showcased its lipid product range to global pharma and vaccine producers at the CPHI exhibition held in Frankfurt, Germany from 1st to 3rd November, 2022, a statement from the company has notified.
It included applications of lipids in developing thermostable vaccines and formulations, cancer therapy based on liposomes and treatment of chronic auto-immune and neuro-muscular diseases like myasthenia gravis and multiple sclerosis, the statement mentioned.
There was specific interest in new upcoming technologies based on lipids, especially in the development of antibodies, RNA, oligonucleotides and several advanced medical products. There was also interest in VAV’s lipids for developing animal vaccines and aquaculture. The applications of lipids in reformulating generic drugs to make them more efficient also received significant attention from global generic pharma companies, added the statement.
During the event, the company met with several officials from some of the pharma, nutra and healthcare companies of the world. Discussions were held with global multinationals for possible strategic partnerships, based on VAV’s manufacturing capabilities to supply lipids to exacting global standards, the statement concluded.